Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVRONASDAQ:BCDANASDAQ:HARPNYSE:RCOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$1.21+1.7%$1.27$0.57▼$1.70$54.28M1.22269,863 shs204,967 shsBCDABioCardia$0.38+2.7%$0.41$0.32▼$2.92$9.89M1.47317,708 shs29,240 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/ARCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/A7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO-0.42%-4.44%-5.95%-12.87%+33.15%BCDABioCardia-3.61%-2.97%-12.90%-20.29%-81.89%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.72%+301.29%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBIO1.3965 of 5 stars3.04.00.00.00.01.70.6BCDABioCardia2.9977 of 5 stars3.35.00.00.02.63.30.0HARPHarpoon Therapeutics1.2421 of 5 stars2.20.00.04.70.04.20.0RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO2.00Hold$2.0065.29% UpsideBCDABioCardia2.50Moderate Buy$4.00962.13% UpsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsideRCORRenovacorN/AN/AN/AN/ACurrent Analyst RatingsLatest BCDA, AVRO, HARP, and RCOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform2/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/A$0.29 per share4.15$2.13 per shareN/ABCDABioCardia$477K21.21N/AN/A($0.07) per share-5.38HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)BCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ALatest BCDA, AVRO, HARP, and RCOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023BCDABioCardia-$0.11-$0.09+$0.02-$0.09$0.20 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A15.7815.78BCDABioCardiaN/A0.400.40HARPHarpoon TherapeuticsN/A1.891.89RCORRenovacorN/A6.606.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%BCDABioCardia20.57%HARPHarpoon Therapeutics74.01%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%BCDABioCardia23.90%HARPHarpoon Therapeutics17.00%RCORRenovacor14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.86 million40.73 millionOptionableBCDABioCardia1626.87 million20.45 millionOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableBCDA, AVRO, HARP, and RCOR HeadlinesSourceHeadlineRecord Store Day 2024: How to Flatten Warped Vinyl Records at Homecnet.com - April 22 at 7:23 PMThe best record players 2024: Top turntables for any budgettomsguide.com - April 20 at 3:40 PMBest turntables 2024: Bluetooth record players for Record Store Daystuff.tv - April 20 at 10:39 AMNews of Recordnewsandsentinel.com - March 30 at 4:05 AMNHL opening night delivers record viewership on ESPNnhl.com - November 6 at 5:27 PMState Pension payments worth over £2,000 each month for older people living in these European countriesdailyrecord.co.uk - October 30 at 1:55 PMThe best early Black Friday turntable deals 2023whathifi.com - October 29 at 12:00 AMAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisdailyrecord.co.uk - October 27 at 2:36 PMNYC shoplifting hit record highs last year: ‘We can’t stop them’nypost.com - October 24 at 1:35 PMTranscriptional control of the inflammatory responsenature.com - October 18 at 7:59 AMRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directorsfinance.yahoo.com - October 17 at 7:56 AMFolwell criticizes fellow Republicans on public records rollbackwral.com - October 14 at 8:16 PMBest Bluetooth turntables 2023: wireless record players for streaming vinylwhathifi.com - October 11 at 12:09 PMHere’s why you shouldn’t record meltdowns on an airplane: FAA insidernypost.com - October 3 at 11:57 PMRecord-breaking heat wave peaking in Eastern U.S. with highs near 100washingtonpost.com - September 28 at 6:28 PMiOS 17: How to Record a FaceTime Video or Audio Messagemacrumors.com - September 15 at 7:16 PMThis was the world’s hottest summer on record ‘by a large margin’washingtonpost.com - September 9 at 6:12 PMCapCut breaths life into new-wave blogging for modern businessesdailyrecord.co.uk - September 6 at 9:28 AMMontauk trailer listing eyes record — even with a price cuttherealdeal.com - September 5 at 11:26 PMRecord-Breaking Summer: Portland, New Orleans Break Daily High Temperature Records After Hottest July Everforbes.com - August 23 at 10:13 AMRecord-Breaking Summer: Jacksonville, Miami Break Daily High Temperature Records, After Hottest July Everforbes.com - August 16 at 6:56 PMPhoenix, New Orleans, Baton Rouge Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 11 at 7:09 PMPhoenix, Dallas, Little Rock Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 9 at 12:55 AMPhoenix just posted the hottest month ever observed in a U.S. citywashingtonpost.com - August 5 at 9:27 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsGE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsBuy the Dip in Paychex, Inc. for a Pay Check at RetirementApril 2, 2024 11:07 AMView Buy the Dip in Paychex, Inc. for a Pay Check at RetirementAll Headlines Company DescriptionsAVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.RenovacorNYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.